key: cord-0272139-a59h5n42 authors: Sun, B. B.; Kurki, M. I.; Foley, C. N.; Mechakra, A.; Chen, C.-Y.; Marshall, E.; Wilk, J. B.; Biogen Biobank Team,; Chahine, M.; Chevalier, P.; Christe, G.; FinnGen,; Palotie, A.; Daly, M. J.; Runz, H. title: Genetic associations of protein-coding variants in human disease date: 2021-10-16 journal: nan DOI: 10.1101/2021.10.14.21265023 sha: fbc19b91a4122e663ea7e5803d2e7e16593724c3 doc_id: 272139 cord_uid: a59h5n42 Genome-wide association studies (GWAS) have identified thousands of genetic variants linked to the risk of human disease. However, GWAS have thus far remained largely underpowered to identify associations in the rare and low frequency allelic spectrum and have lacked the resolution to trace causal mechanisms to underlying genes. Here, we combined whole exome sequencing in 392,814 UK Biobank participants with imputed genotypes from 260,405 FinnGen participants (653,219 total individuals) to conduct association meta-analyses for 744 disease endpoints across the protein-coding allelic frequency spectrum, bridging the gap between common and rare variant studies. We identified 975 associations, with more than one-third of our findings not reported previously. We demonstrate population-level relevance for mutations previously ascribed to causing single-gene disorders, map GWAS associations to likely causal genes, explain disease mechanisms, and systematically relate disease associations to levels of 117 biomarkers and clinical-stage drug targets. Combining sequencing and genotyping in two population biobanks allowed us to benefit from increased power to detect and explain disease associations, validate findings through replication and propose medical actionability for rare genetic variants. Our study provides a compendium of protein-coding variant associations for future insights into disease biology and drug discovery. Inherited protein-coding and non-coding DNA variations play a role in the risk, onset, and 44 progression of human disease. Traditionally, geneticists have dichotomized diseases as either 45 caused by coding mutations in single genes that tend to be rare, highly penetrant, and often 46 compromise survival and reproduction (often termed "Mendelian" diseases), or alternatively 47 as common diseases that show a complex pattern of inheritance influenced by the joint 48 contributions of hundreds of low-impact, typically non-coding genetic variants (often termed 49 "complex" diseases). For both rare and common conditions, large human cohorts 50 systematically characterized for a respective trait of interest have enabled the identification of 51 thousands of disease-relevant variants through either sequencing-based approaches or genome-52 wide association studies (GWAS). Nevertheless, the exact causal alleles and mechanisms that 53 underlie associations of genetic variants to disease have thus far remained largely elusive 1 . 54 55 In recent years, population biobanks have been added to the toolkit for disease gene discovery. 56 Biobanks provide the opportunity to simultaneously investigate multiple traits and diseases at 57 once and uncover relationships between previously unconnected phenotypes. For instance, the 58 UK Biobank (UKB) is a resource that captures detailed phenotype information matched to 59 genetic data for over 500,000 individuals and, since its inception, has facilitated biomedical 60 discoveries at an unprecedented scale 2 . We and others have recently reported on the ongoing 61 efforts to sequence the exomes of all UKB participants and link genetic findings to a broad 62 range of phenotypes 3-5 . We also established FinnGen (FG), an academic-industry collaboration 63 to identify genotype-phenotype correlations in the Finnish founder population with the aim to 64 better understand how the genome affects health (https://www.finngen.fi). Finland is a well-65 established genetic isolate and a unique gene pool distinguishes Finns from other Europeans 6 . 66 The distinct Finnish haplotype structure is characterized by large blocks of co-inherited DNA 67 7 allele frequency (MAF) range of 0.01% to 0.25% (Figure 1d Table 3) . 157 Importantly, 17% of known (UKB; 19% in FG), but 31% of novel (UKB; 28% in FG) 158 associations had a MAF<5%. Correspondingly, 5% of known (UKB; 6% in FG) and 15% of 159 novel (UKB; 10% in FG) associations had a MAF<1%, highlighting the power gained through 160 our approach especially in the low and rare allele frequency spectrum (Figure 1e , 161 Supplementary Table 3) . 162 163 Mapping associations to genes, we found the majority of gene loci (81.2% at p<5x10 -8 , MHC 164 region counted as one locus) to be associated with a single disease cluster (Extended Data 165 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint established pleiotropic regions such as the MHC, APOE, PTPN22, GCKR, SH2B3 and FUT2 167 (Figure 1a) . For instance, in addition to a known association with breast cancer, we found 168 variants in CHEK2 as associated with the risk of colorectal and thyroid cancers, uterine 169 leiomyoma, benign meningeal tumours and ovarian cysts. Also, in addition to a known 170 association with prostate hyperplasia, we found an ODF3 missense variant (rs72878024) to be 171 associated with risk of uterine leiomyoma, benign meningeal tumour, lipoma and polyps in the 172 female genital tract (Supplementary Table 3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 205 We leveraged the coding variant associations identified in our study to generate biological 206 insights for a range of distinct genes, pathways and diseases and in the following exemplify 207 the broad utility of our resource through a set of selected use cases. 208 209 New roles of coagulation pathway proteins in conferring pulmonary embolism risk 210 We found known and novel associations with pulmonary embolism (PE) risk, including two 211 rare variant associations (average MAF<1%) in genes encoding components of the coagulation 212 cascade at the convergent common pathway (Figure 2a) . For instance, we discovered a rare 213 missense mutation in F10, enriched by ~5-fold in FG (rs61753266:A; Glu142Lys; MAF=0.33% 214 [UKB], 1.85% [FG]), to be protective against PE (log[OR]=-0.44, p=2.9x10 -9 ). This variant 215 has been associated with reduced plasma coagulation factor X (beta=-1.12, p=2.0x10 -8 ) and 216 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure 225 2b). We performed Mendelian randomisation (MR) using rs4525 and rs61753266 as 226 instruments to estimate the relative reduction in PE risk due to reduced F5 (betaMR=0.57, 227 p=1.0x10 -15 ) and F10 levels (F10: betaMR=0.40, p=2.9x10 -9 ; F10a: betaMR=0.28, p=2.9x10 -9 ) 228 respectively (Figure 2b) . MR results support the expected clinical indication of factor X 229 inhibitors in thromboembolic diseases and the hypothesis that developing drugs inhibiting 230 factor V will also likely be beneficial for PE. We also found a rare variant in fibrinogen (FGB We interrogated the sentinel variants identified in this study for associations with 117 238 quantitative biomarkers spanning eight categories in UKB (Supplementary Table 8 ). At a 239 multiple testing adjusted threshold of p<1x10 -6 , we found 108 of the biomarkers to be 240 associated with at least one of 417 sentinel variants across 239 regions (Figure 3a , 241 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint [UKB], 0.5% [FG] ) that is associated with increased enzymatic activity of alcohol 248 dehydrogenase and reduced alcohol tolerance, is also associated with reduced risk of alcohol-249 related disorders (alcoholic liver disease: log[OR]=-1.08, p=1.5x10 -9 ; mental and behavioural 250 disorders due to alcohol: log[OR]=-0.82, p=1.2x10 -33 ) and increased risk of gout 251 (log[OR]=0.39, p=3.3x10 -10 ). Notably, the alcohol dependence disorder-promoting ADH1B 252 allele (C) is also associated with reduced IGF-1 (beta=-0.11, p=1.5x10 -51 ) and vitamin D levels 253 (beta=-0.049, p=2.6x10 -10 ), increased levels of liver enzymes (alkaline phosphatase: 254 beta=0.087, p=3.1x10 -37 ; gamma-glutamyl transferase: beta=0.041, p=1.62x10 -9 ) and total 255 bilirubin (beta=0.031, p=5.1x10 -7 ), macrocytosis with increased mean corpuscular volume 256 (beta=0.047, p=4.2x10 -12 ) and mean corpuscular haemoglobin (beta=0.048, p=1.4x10 -12 ), as 257 well as reduced erythrocyte count (beta=-0.034, p=3.2x10 -8 ). The gout risk reducing C allele 258 is associated with reduced urate levels (beta=-0.061, p=1.4x10 -21 ). 259 260 A deletion in SLC34A1 is associated with multiple blood and urinary abnormalities 261 Cross-referencing with biomarkers provided mechanistic insights into novel findings. For 262 instance, we discovered a novel association between a low frequency in-frame deletion in 263 SLC34A1 (rs1460573878, also known as rs876661296; MAF=2.6% [UKB], 2.7% [FG]; 264 p.Val91_Ala97del) coding for the type II sodium phosphate cotransporter, NPT2a, which is 265 expressed specifically in renal proximal tubular cells, to be associated with increased risk of 266 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint renal (log[OR]=0.24, p=4.0x10 -9 ) and urinary tract stones (log[OR]=0.21, p=6.8x10 -9 ). The 267 deletion has previously been implicated in hypercalciuric renal stones 20,21 and autosomal 268 recessive idiopathic infantile hypercalcaemia 22 in family studies. The variant is also associated 269 with increased serum calcium (beta=0.047, p=5.4x10 -11 ) and reduced phosphate (beta=-0.075, 270 p=3.3x10 -26 ), consistent with a disrupted function/cell surface expression of the transporter 22 271 (Figure 3b) . We further find associations with increased levels of serum urate (beta=0.048, 272 p=4.5x10 -17 ), suggesting an increased risk also of uric acid stones. Additionally, we found 273 associations with increased erythrocyte count (beta=0.035, p=4.7x10 -10 ), haemoglobin 274 concentration (beta=0.033, p=7.7x10 -10 ) and haematocrit percentage (beta=0.036, p=9.9x10 -11 ), 275 suggesting increased renal-driven erythropoiesis (Figure 3b) p=4.7x10 -4 ). Association of rs555607708 with clinical haematology traits showed statistically 290 significant associations with increased blood cell counts for both, myeloid (leukocytes, 291 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint neutrophils, platelets at p<1x10 -6 ; monocyte and erythrocytes at p<1x10 -3 ) and lymphoid 292 (lymphocytes, p=5.7x10 -17 ) lineages (Figure 3c) . Furthermore, we found associations with 293 increased mean platelet volume (MPV, p=1.3x10 -16 ) and platelet distribution width (PDW, 294 p=5.2x10 -13 ), consistent with increased platelet activation and previous associations of MPV 295 and PDW with chronic myeloid leukaemia 25 . We also found associations with decreased mean 296 corpuscular haemoglobin (p=7.8x10 -12 ) and mean corpuscular volume (p=5.3x10 -10 ), 297 suggesting predisposition to haematological cancers by loss-of CHEK2 function is 298 accompanied by a microcytic red blood cell phenotype (Figure 3c) . 299 300 We cross-referenced genes with significant coding variant associations with drug targets using 302 the therapeutic targets database 26 . We found 66 genes with trait cluster associations that are the 303 targets of either approved drugs (26 genes) or drugs currently being tested in clinical trials (40 304 genes), among these, 14 in phase 3 trials (Supplementary Table 10) . We found a statistical 305 enrichment for significant genes in our study to also be approved drug targets (26/482; 306 compared with a background of 569 approved targets/19,955 genes, OR=1.9, p=0.0024), which 307 is in line with previous estimates of a higher success rate for drug targets supported by 308 genetics 27,28 . Sensitivity analyses using more stringent association p-value thresholds further 309 increased these probability estimates (p=5x10 -9 [OR 2.3, p=0.00070]; p=5x10 -10 [OR 2.5, 310 p=0.00037], supporting previous observations that the stronger the genetic association, the 311 higher the likelihood of therapeutic success (Supplementary Table 11 ). In addition to 312 providing further support for well-established drug target associations such as between PCSK9 313 loss-of-function and hypercholesterolaemia, or F10 loss-of-function and venous 314 thromboembolism, we also found an association between a common missense variant 315 (rs231775:G) in CTLA4 with increased risk of thyrotoxicosis (log[OR]=0.12, p=8.5x10 -13 ). 316 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint Since this variant is also a blood eQTL for decreased CTLA4 expression 29 (Z-score=-6.91, 317 p=5.0x10 -12 ), the association between genetic CTLA4 reduction and thyroid dysfunction might 318 contribute to the adverse event of hyperthyroidism in cancer patients treated with CTLA4 319 inhibitors 30 . 320 321 Genetics can inform drug discovery also on alternative indications for repurposing. For 322 example, TYK2 inhibitors are being tested in clinical trials for various autoimmune and 323 psoriatic diseases 31 . Consistent with previous GWAS 10 , we found a missense variant in TYK2 324 (rs34536443:C) to be associated with reduced risk of rheumatoid arthritis and psoriatic diseases 325 Table 3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Specifically, we related expectation maximization clustering of AF associated variants with 393 homogenous directional effects on pulse rate (Methods). Among the AF sentinel variants from 394 our coding variant association analyses, we found the two above described clusters of variants 395 in SCN10A (rs6795970) and HCN4 (rs151004999), suggestive of two genetic components of 396 AF that can increase and decrease pulse rate, respectively (Figure 4a, left) . Identifying 397 components of AF with diverging directionality on pulse rate is not surprising given clinically 398 AF can be driven by both tachycardia and bradycardia through distinct mechanisms 48 . As 399 sensitivity analyses, we used sentinel variants from a recent AF GWAS 32 where the candidate 400 gene sets overlapped those in our study and found concordant patterns (Figure 4a , left-middle, 401 Supplementary Table 13) . We also included all sentinel variants in the AF GWAS loci 32 and 402 found additional clusters with differing impact on pulse rate (Figure 4a, right-middle) . 403 Conversely, as expected, permuting pulse rate led to no clustering and null associations 404 between AF and pulse (Figure 4a, right) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Supplementary Information, Supplementary Figure Pro41Ser 1 Here, we have conducted the to date largest association study of protein-coding genetic variants 434 against hundreds of disease endpoints ascertained from two massive population biobanks, UK 435 Biobank and FinnGen. We report novel disease associations, most notably in the rare and low 436 allelic frequency spectrum, replicate and assign putative causalities to many previously 437 reported GWAS associations, and leverage the insights gained to elucidate disease 438 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint mechanisms. In addition to a substantial gain in power over previous studies, our analyses 439 benefit from replication between two population cohorts, increasing the robustness of our 440 findings and setting the stage for future similar studies in ethnically more diverse populations. 441 442 Importantly, our study identifies both, pathogenic variants residing in monogenic disease genes 443 to impact the risk for related complex conditions, as well as new, likely causal sentinel variants 444 within GWAS loci in genes with known and novel biological roles in the respective GWAS 445 trait. With this, our study is one of the first to help bridge the gap between common and rare 446 disease genetics across a broad range of conditions and provides support for the hypothesis that 447 the genetic architecture of many diseases is continuous 1 . As reflected in a recent schizophrenia 448 study 50 , GWAS tend to identify association signals primarily for variants with MAF>2%, while 449 most variants identified through exome sequencing are ultra-rare (MAF<0.01%). Of the 975 450 associations identified in our study, 145 are driven by unique variants in the yet little 451 interrogated rare and low allelic frequency spectrum that is hypothesized to contribute 452 substantially to the "missing heritability" of many human diseases 51 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint prevalence in the population that warrants follow-up, both experimentally as well as potentially 464 directly in clinical settings to help improve disease outcomes. For instance, our data propose 465 that 6.5% of UKB and FG participants with kidney or urinary tract stones, conditions 466 debilitating >15% of men and 5% of women by 70 years of age 52 , carry a deletion in SLC34A1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint genotyping, and computational advances to analyse genetic and non-genetic data at scale, 489 future studies will be able to assess the genetic contribution to health and disease at even finer 490 resolution. 491 492 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint registries. For disease definition consistency, we reproduced the same Phecode maps using the 520 same ICD-10 definitions in UKB. In particular, we expertly curated 15 neurological 521 phenotypes using ICD10 codes. We retained phenotypes where the similarity score (Jaccard 522 index: ICD10FG Ç ICD10UKB / ICD10FG È ICD10UKB) was >0.7 and additionally excluded 523 spontaneous deliveries and abortions. 524 525 Phecodes and ICD10 coded phenotypes were first mapped to unified disease names and disease 526 groups using mappings from Phecode, "PheWAS" and "icd" R packages followed by manual 527 curation of unmapped traits and diseases groups, mismatched and duplicate entries. Disease 528 endpoints were mapped to Experimental Factor Ontology (EFO) terms using mappings from 529 EMBL-EBI and Open Targets based on exact disease entry matches followed by manual 530 curation of unmapped traits. 531 532 Disease trait clusters were determined through first calculating the phenotypic similarity via 533 the cosine similarity, then determining clusters via hierarchical clustering on the distance 534 matrix (1-similarity) using the Ward algorithm and cutting the hierarchical tree, after inspection, 535 at height 0.8 to provide the most semantically meaningful clusters. 536 537 Genetic data processing 538 UKB genetic QC 539 UKB genotyping and imputation were performed as described previously 2 . WES data for UKB 540 participants were generated at the Regeneron Genetics Center (RGC) as part of a collaboration 541 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint between AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, 542 Pfizer, Regeneron and Takeda with the UK Biobank. WES data were processed using the RGC 543 SBP pipeline as described in 3,55 . RGC generated a QC-passing "Goldilocks" set of genetic 544 variants from a total of 454,803 sequenced UK Biobank participants for analysis. Additional 545 QC were performed prior to association analyses as detailed below. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint detailed in 58 . In brief, the first step fits a whole genome regression model for individual trait 567 predictions based on genetic data using the leave one chromosome out (LOCO) scheme. We 568 used a set of high-quality genotyped variants: minor allele frequency (MAF)>5%, minor allele 569 count (MAC)>100, genotyping rate >99%, Hardy-Weinberg equilibrium (HWE) test p>10 −15 , 570 <5% missingness and linkage-disequilibrium (LD) pruning (1000 variant windows, 100 sliding 571 windows and r 2 <0.8). Traits where the step 1 regression failed to converge due to case 572 imbalances were subsequently excluded from subsequent analyses. The LOCO phenotypic 573 predictions were used as offsets in step 2 which performs variant association analyses using 574 the approximate Firth regression detailed in 58 when the p-value from the standard logistic 575 regression score test is below 0.01. Standard errors (SEs) were computed from the effect size 576 estimate and the likelihood ratio test p-value. To avoid issues related to severe case imbalance 577 and extremely rare variants, we limited association test to phenotypes with >100 cases and for 578 variants with MAC³5 in total samples and MAC³3 in cases and controls. The number of 579 variants used for analyses varies for different diseases as a result of the MAC cut-off for 580 different disease prevalence. The association models in both steps also included the following 581 covariates: age, age 2 , sex, age*sex, age 2 *sex, first 10 genetic principle components (PCs). 582 583 Association analyses in FG were performed using mixed model logistic regression method 584 SAIGE v0.39 59 . Age, sex, 10 PCs and genotyping batches were used as covariates. For null 585 model computation for each endpoint each genotyping batch was included as a covariate for 586 an endpoint if there were at least 10 cases and 10 controls in that batch to avoid convergence 587 issues. One genotyping batch need be excluded from covariates to not have them saturated. We 588 excluded Thermo Fisher batch 16 as it was not enriched for any particular endpoints. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint with MAF<1%. The remaining variants were LD pruned with a 1Mb window and r 2 threshold 592 of 0.1. This resulted in a set of 59,037 well-imputed not rare variants for GRM calculation. 593 SAIGE options for null computation were: "LOCO=false, numMarkers=30, 594 traceCVcutoff=0.0025, ratioCVcutoff=0.001". Association tests were performed phenotypes 595 with case counts >100 and for variants with minimum allele count of 3 and imputation info >0.6 596 were used. 597 We additionally performed sex-specific associations for a subset of gender-specific diseases 599 (60 female diseases and in 50 disease clusters, 14 male diseases and in 13 disease clusters) in 600 both FG and UKB using the same approach without inclusion of sex-related covariates 601 (Supplementary Table 2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint independent regions (±500Kb) and further restricted each independent variant (r 2 =0.1) to the 617 most significant sentinel variant for each unique gene. For defining region associations across 618 traits, we merged overlapping independent regions for each individual trait. 619 620 Cross reference with known genetic associations 621 We cross-referenced the sentinel variants and their proxies (r 2 >0.2) for significant associations 622 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. The missense variants rs4525 and rs61753266 in F5 and F10 genes were taken as genetic 647 instruments for MR analyses. To assess potential that each factor level is causally associated 648 with PE we employed two-sample MR using summary statistics, with effect of the variants on 649 their respective factor levels obtained from previous large scale (protein quantitative trait loci) 650 pQTL studies 13,15 . Let !" denote the estimated causal effect of a factor level on PE risk and ! , 651 " be the genetic association with a factor level (FV, FX or FXa) and PE risk respectively. 652 Then, the MR ratio-estimate of !" is given by: 653 where the corresponding standard error se( !" ), computed to leading order, is: 655 To assess evidence of several distinct causal mechanisms by which atrial fibrillation (AF) may 659 influence pulse rate (PR) we used MR-Clust 47 . In brief, MR-Clust is a purpose-built clustering 660 algorithm for use in univariate MR analyses. It extends the typical MR assumption that a risk 661 factor can influence an outcome via a single causal mechanism 63 to a framework that allows 662 one or more mechanisms to be detected. When a risk-factor affects an outcome via several 663 mechanisms, the set of two-stage ratio-estimates can be divided into clusters, such that variants 664 within each cluster have similar ratio-estimates. As shown in 47 , two or more variants are 665 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint members of the same cluster if and only if they affect the outcome via the same distinct causal 666 pathway. Moreover, the estimated causal effect from a cluster is proportional to the total causal 667 effect of the mechanism on the outcome. We included variants within clusters where the 668 probability of inclusion >0.7. We used MR-Clust algorithm allowing for singletons/outlier 669 variants to be identified as their own "clusters" to reflect the large but biologically plausible 670 effect sizes seen with rare and low frequency variants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 16, 2021. ; https://doi.org/10.1101/2021.10.14.21265023 doi: medRxiv preprint A brief history of human disease genetics The UK Biobank resource with deep phenotyping and genomic data. 785 Exome sequencing and characterization of 49,960 individuals 787 in the UK Biobank Advancing Human Genetics Research and Drug Discovery 789 through Exome Sequencing of the UK Biobank. medRxiv Surveying the contribution of rare variants to the genetic architecture 792 of human disease through exome sequencing of 177,882 UK Biobank participants. 793 bioRxiv Molecular genetics of the Finnish disease 795 heritage Distribution and medical impact of loss-of-function variants in the 797 Finnish founder population Exome sequencing of Finnish isolates enhances rare-variant 800 association power High-resolution population-specific recombination rates and their 802 effect on phasing and genotype imputation The NHGRI-EBI GWAS Catalog of published genome-wide 805 association studies, targeted arrays and summary statistics 2019 PhenoScanner: a database of human genotype-phenotype 808 associations ClinVar: improving access to variant interpretations and 811 supporting evidence Genomic atlas of the human plasma proteome Glu102Lys on the factor X function in a patient with a doubly homozygous factor X 817 deficiency (Gla14Lys and Glu102Lys) Connecting genetic risk to disease end points through the human 819 blood plasma proteome Factor V Leiden thrombophilia A meta-analysis of 120 246 individuals identifies 18 new loci for 824 fibrinogen concentration Association of genomic loci from a cardiovascular gene SNP 827 array with fibrinogen levels in European Americans and African-Americans from six 828 cohort studies: the Candidate Gene Association Resource (CARe) Genetic Variants in the FGB and FGG Genes Mapping in the Beta 831 and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative 832 Fibrinogen Disorders Associated with a Thrombotic Phenotype NPT2a gene variation in calcium nephrolithiasis with renal 835 phosphate leak Fourteen monogenic genes account for 15% of 837 nephrolithiasis/nephrocalcinosis Autosomal-Recessive Mutations in SLC34A1 Encoding 840 Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia Germ line variants predispose to both JAK2 V617F clonal 843 hematopoiesis and myeloproliferative neoplasms CHEK2*1100delC and 846 risk of chronic lymphocytic leukemia Normal platelet counts mask abnormal thrombopoiesis in patients with 849 chronic myeloid leukemia Therapeutic target database 2020: enriched resource for facilitating 852 research and early development of targeted therapeutics The support of human genetic evidence for approved drug 855 indications Are drug targets with genetic support twice 857 as likely to be approved? Revised estimates of the impact of genetic support for drug 858 mechanisms on the probability of drug approval Unraveling the polygenic architecture of complex traits using blood 861 eQTL metaanalysis. bioRxiv The Current Understanding of the Endocrine Effects From Immune 863 Checkpoint Inhibitors and Recommendations for Management Phenome-wide association studies across large population cohorts 866 support drug target validation Biobank-driven genomic discovery yields new insight into atrial 869 fibrillation biology Multi-ethnic genome-wide association study for atrial fibrillation A Missense Variant in PLEC Increases Risk of Atrial 874 NRMT2 is an N-terminal monomethylase that primes for its 876 homologue NRMT1 An asparagine/glycine switch governs product specificity of human N-878 terminal methyltransferase NTMT2 The Genotype-Tissue Expression (GTEx) project Proteomics. Tissue-based map of the human proteome Genetic variation in SCN10A influences cardiac conduction SCN5A Variants: Association With Cardiac Disorders Multiple loss-of-function mechanisms contribute to SCN5A-related 891 familial sick sinus syndrome Congenital sick sinus syndrome caused by recessive mutations in 894 the cardiac sodium channel gene (SCN5A) Sodium channel mutations and susceptibility to heart failure and 897 atrial fibrillation The role of mutations in the SCN5A gene 899 in cardiomyopathies Pacemaker activity of the human sinoatrial node: 902 effects of HCN4 mutations on the hyperpolarization-activated current Clustering of 905 genetic variants in Mendelian randomization with similar causal estimates Evaluating and managing bradycardia PITX2-dependent gene regulation in atrial 910 fibrillation and rhythm control Mapping genomic loci prioritises genes 913 and implicates synaptic biology in schizophrenia. medRxiv Missing heritability and strategies for finding the underlying 916 causes of complex disease Genetics of kidney stone disease Validating therapeutic targets through 920 human genetics Systematic comparison of phenome-wide association study of 922 electronic medical record data and genome-wide association study data A catalog of associations between rare coding variants and 925 COVID-19 outcomes. medRxiv The mutational constraint spectrum quantified from variation 928 in 141,456 humans The Ensembl Variant Effect Predictor Computationally efficient whole genome regression for 932 quantitative and binary traits. bioRxiv Efficiently controlling for case-control imbalance and sample 935 relatedness in large-scale genetic association studies METAL: fast and efficient meta-analysis of 938 genomewide association scans Second-generation PLINK: rising to the challenge of larger and 941 richer datasets Inferring Causal Relationships Between Risk 945 Factors and Outcomes from Genome-Wide Association Study Data UniProt: the universal protein knowledgebase in 2021